SUMMARY
induce mucosal tolerance after pretreatment with pertussis in rats27 and also that pertussis modulates both vascular permeability28 and T-cell function29 and inhibits the induc tion of antigen-induced peripheral T-cell tolerance in experimental allergic encephalomyelitis (EAE) in mice. 30 In an attempt to overcome the complexity of mUltiple putative retinal autoantigens in EAU and additional exo genous factors (for example the use of pertussis toxin, which induces pronounced lymphocytosis, acts as a T-cell mitogen and increases immunoglobulin E responses), we have studied a model of EAU induced by a heterologous mixture of retinal antigens: retinal extract (RE). The inflammatory response was monitored by both a clinical and customised histological grading system (Table 1) . 3 1 Because most previous studies of immunomodulation of EA U in Lewis rats have depended upon the acute or hyper acute model, it has been difficult to evaluate, by histologi- Note the reduced amount of inflammatory cell infiltrate within the retina compared with (B).
The main features are total loss of ROS (two arrows) and development of fihrovascular new growth (single arrow). A. D. DICK ET AL.
IMMUNOMODULATION OF EAU

MU COSAL TOLERAN CE INDU CTION IN EAU
We have studied the immunosuppressive effect of intra nasal inoculation of microgram quantities of a highly uveitogenic mixture of retinal antigens, RE, on RE induced EAU, prior to and after immunisation with RE.
Within these groups of experiments EAU was induced with RE and CFA but without the addition of pertussis toxin so as to avoid any potential effect on vascular per meability and suppressor T-cell function. Table II PBS. phosphate-buffered saline; RE. retinal extract; S-Ag. S-antigen, Table IV documents the results of ear lobe DTH responses in both control ani mals and tolerised animals 12 days after immunisation with RE. There was a significant reduction in reactivity to RE in the tolerised animals, which also generated a DTH response to a non-specific antigen (PPD) present in CFA but not RE, that was equivalent to the response in the con trol group of animals. Tolerised animals also mount a normal humoral response to RE, which rises over 3weeks after immunisation and was not statistically different from that in control animals (Fig. 3) . particularly with tolerogenic and non -autoimmunogenic chemically modified fonns, would exploit a natural and powerful phenomenon of tolerance induction and immunosuppression, and offers a novel approach to speci fic immune targeted therapy in autoimmune disease.
Although an attractive therapeutic strategy, it is important to establish that tolerance therapy does not exacerbate the disease in sensitised individuals or during disease relapse.
One practical limitation at present is that neither oral nor intranasal tolerance induction appears to suppress active disease consistently and significantly, but this may be because the animal model is not chronic.
The immunotherapeutic approaches outlined in this paper all have difficulties. For example, the generation of peptide blocking therapy will not become possible until uveitogenic peptides for each patient can be detected. 
